How to buy Entera Bio stock - 22 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Entera Bio stock

Own Entera Bio stock in just a few minutes.

Entera Bio Ltd is a biotechnology business based in the US. Entera Bio shares (ENTX) are listed on the NASDAQ and all prices are listed in US Dollars. Entera Bio employs 19 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Entera Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ENTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Entera Bio share price

Use our graph to track the performance of ENTX stocks over time.

Entera Bio shares at a glance

Information last updated 2021-03-18.
52-week range$1.00 - $6.47
50-day moving average $2.03
200-day moving average $1.44
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.05

Buy Entera Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Entera Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Entera Bio financials

Revenue TTM $246,000
Gross profit TTM $26,000
Return on assets TTM -98.17%
Return on equity TTM -228.51%
Profit margin 0%
Book value $0.31
Market capitalisation $123.4 million

TTM: trailing 12 months

Shorting Entera Bio shares

There are currently 135,526 Entera Bio shares held short by investors – that's known as Entera Bio's "short interest". This figure is 13.4% down from 156,528 last month.

There are a few different ways that this level of interest in shorting Entera Bio shares can be evaluated.

Entera Bio's "short interest ratio" (SIR)

Entera Bio's "short interest ratio" (SIR) is the quantity of Entera Bio shares currently shorted divided by the average quantity of Entera Bio shares traded daily (recently around 589243.47826087). Entera Bio's SIR currently stands at 0.23. In other words for every 100,000 Entera Bio shares traded daily on the market, roughly 230 shares are currently held short.

However Entera Bio's short interest can also be evaluated against the total number of Entera Bio shares, or, against the total number of tradable Entera Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Entera Bio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Entera Bio shares in existence, roughly 10 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable Entera Bio shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Entera Bio.

Find out more about how you can short Entera Bio stock.

Entera Bio share dividends

We're not expecting Entera Bio to pay a dividend over the next 12 months.

Entera Bio share price volatility

Over the last 12 months, Entera Bio's shares have ranged in value from as little as $1 up to $6.47. A popular way to gauge a stock's volatility is its "beta".

ENTX.US volatility(beta: 1.34)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entera Bio's is 1.3386. This would suggest that Entera Bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Entera Bio overview

Entera Bio Ltd. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site